Hypertensive Nephrosclerosis — Viva

Q1: Benign vs malignant — the histological divide (2 min)

"Walk me through the histological distinction between benign and malignant hypertensive nephrosclerosis, and link each lesion to a mechanism."

• Benign (chronic) nephrosclerosis is the lesion of sustained pressure overload: the afferent (preglomerular) arteriole develops hyaline arteriolosclerosis — pink, homogenous deposition of plasma proteins and lipids in the intima/media, thickening the wall, narrowing the lumen and rendering the vessel rigid. Mechanistically, this abolishes the myogenic autoregulation that normally shields the glomerulus from systemic pressure swings. Two consequences follow: when systemic pressure is high it is transmitted directly to the glomerulus (glomerular hypertension, hyperfiltration injury, FSGS-like scarring); when systemic pressure falls the stiff afferent cannot dilate, and the glomerulus becomes ischaemic (solidified glomerulosclerosis, periglomerular fibrosis, tubular atrophy, interstitial fibrosis). Both converge on nephron loss, producing the small, granular, contracted kidney.

• Malignant-phase hypertension is the lesion of severe, abrupt pressure overload: the arteriolar wall fails outright, and plasma proteins and fibrin flood the intima/media, producing fibrinoid necrosis — bright-pink, acellular, amorphous material on light microscopy. In the larger interlobular arteries, a concentric proliferation of myofibroblasts produces the 'onion-skinning' (hyperplastic arteriolitis). Endothelial injury activates platelets and shears red cells, producing a thrombotic microangiopathy with schistocytes, falling platelets, AKI and rising LDH.

• Clinical correlate: the same histological divide maps onto the clinical divide — benign is slow CKD with a bland sediment; malignant is an emergency with grade III–IV retinopathy, encephalopathy and AKI.

Q2: Why an ACE inhibitor/ARB is uniquely renoprotective (3 min)

"Why is an ACE inhibitor or ARB first-line for hypertensive nephrosclerosis, and how do you monitor a patient after you start one?"

• Mechanism: angiotensin II preferentially constricts the efferent arteriole, raising intraglomerular pressure (P_GC) and the protein leak, and directly drives pro-fibrotic signalling (TGF-β, mesangial and podocyte injury). An ACE inhibitor or ARB dilates the efferent arteriole, lowers P_GC, reduces proteinuria, and interrupts the pro-fibrotic cascade — a renoprotection that is independent of the blood-pressure fall. That independence is the answer to the question.

• Landmark evidence: the AASK trial (JAMA 2002) — in African-Americans with hypertensive CKD, the ACE inhibitor ramipril slowed GFR decline and reduced ESKD/proteinuria more than amlodipine or metoprolol at the same BP — established the class as first-line in hypertensive nephrosclerosis.

• Monitoring after starting: recheck creatinine and potassium at 1–2 weeks. A fall in eGFR of up to 30 percent (creatinine rise up to 30 percent) is expected, haemodynamic, and acceptable — it reflects the desired drop in intraglomerular pressure; continue the drug. A fall over 30 percent (creatinine rise over 30 percent), or a potassium over 5.6 mmol/L, should prompt stopping the drug and screening for bilateral renal artery stenosis (renal Doppler, CT or MR angiography) — because the acute efferent dilation, in a kidney dependent on efferent tone to maintain GFR, precipitates AKI.

• Cautions: never combine an ACE inhibitor with an ARB (ONTARGET: harm, no benefit); never in pregnancy (fetopathy — renal agenesis, oligohydramnios, limb contractures, hypoplastic lungs).

Q3: The 25-percent rule — treating a hypertensive emergency (3 min)

"A patient presents in a hypertensive emergency. How fast do you lower the blood pressure, with what, and why?"

• The principle: lower the mean arterial pressure (MAP) by NO MORE than 25 percent in the FIRST HOUR, then to 160/100 mmHg over the next 2–6 hours, then gradually toward normal over the subsequent 24–48 hours.

• The 'why': chronic hypertension shifts the cerebral autoregulation curve to the right — the brain, heart and kidneys have adapted to the higher pressures and depend on them for perfusion. A precipitous fall drops cerebral, coronary and renal perfusion and causes ischaemic stroke, myocardial infarction and acute kidney injury. This is the central, classic pitfall of treating a hypertensive emergency — a patient can be killed by over-zealous lowering.

• Setting and monitoring: admit to HDU/ICU, arterial line, hourly neurology and urine-output checks.

• Agents — a titratable IV agent with rapid onset and short half-life: labetalol (combined α/β-blocker; 20–40 mg IV boluses q10 min to 80 mg, max 300 mg, or 0.5–2 mg/min infusion; first-line, safe in pregnancy); nicardipine (DHP CCB; 5–15 mg/h infusion); clevidipine (ultra-short); nitroprusside (potent, but cyanide toxicity risk in renal failure); esmolol; fenoldopam (D1 agonist, useful in renal impairment).

• Scenario-specific exceptions: aortic dissection is the ONE scenario where you lower rapidly (SBP under 120 within 20 minutes, β-blocker first to lower dp/dt, then a vasodilator); ischaemic stroke is permissive (treat only if over 220/120, or under 185/110 if thrombolysing); intracerebral haemorrhage targets SBP under 140.

• Trap to name: do NOT start an ACE inhibitor/ARB in the acute emergency; do NOT use sublingual or short-acting nifedipine.

Q4: Resistant hypertension and the secondary-cause work-up (2 min)

"When would you suspect a secondary cause of hypertension, and what would your initial work-up look like?"

• Suspect a secondary cause when the hypertension is resistant (BP over target on three agents at optimal doses including a diurect), early-onset (under 30), severe or malignant, has an abrupt onset, or has specific clues in the history or examination.

• Targeted clues and the matching first test:

  • Renovascular disease / renal artery stenosis — abdominal bruit, asymmetrical kidneys (over 1.5 cm difference), flash pulmonary oedema, rising creatinine on an ACEi/ARB → renal Doppler, then CT or MR angiography.
  • Primary aldosteronism — spontaneous or diuretic-induced hypokalaemia, metabolic alkalosis → aldosterone-to-renin ratio (ARR), then saline or captopril suppression, adrenal CT, adrenal vein sampling.
  • Phaeochromocytoma — episodic triad of headache, palpitation and sweating, paroxysmal/labile hypertension → 24-hour fractionated urine metanephrines or plasma free metanephrines.
  • Cushing syndrome — central obesity, striae, bruising, proximal myopathy → 1-mg overnight dexamethasone suppression test, 24-hour urine cortisol, late-night salivary cortisol.
  • Coarctation of the aorta (younger patient, radio-femoral delay) → CT/MR angiography or echocardiography.
  • Obstructive sleep apnoea — loud snoring, witnessed apnoea, daytime somnolence → polysomnography.

• After excluding secondary causes in true resistant hypertension: the most effective fourth agent is spironolactone 25–50 mg OD (PATHWAY-2: superior to bisoprolol or doxazosin) — after confirming adherence and a normal secondary-cause screen.

Q5: The SGLT2 inhibitor — a new foundational therapy (2 min)

"Tell me about the SGLT2 inhibitors in chronic kidney disease — who gets them, at what dose, and on what evidence?"

• Mechanism: SGLT2 inhibitors lower proximal tubular glucose and sodium reabsorption, increasing sodium delivery to the macula densa and restoring tubuloglomerular feedback — this constricts the afferent arteriole and lowers intraglomerular pressure, reducing hyperfiltration injury.

• Indication: now recommended for all patients with CKD (eGFR down to ~20 mL/min/1.73 m²), on top of maximum-tolerated RAAS blockade, regardless of whether they have diabetes.

• Agents and dose: dapagliflozin 10 mg OD or empagliflozin 10 mg OD.

• Evidence: CREDENCE (NEJM 2019) — canagliflozin in diabetic kidney disease; DAPA-CKD (NEJM 2020) — dapagliflozin reduced the composite of sustained eGFR decline, ESKD or renal/cardiovascular death by about 39 percent, with benefit seen regardless of diabetes; EMPA-KIDNEY (NEJM 2023) — empagliflozin confirmed a 28 percent relative risk reduction across a broad CKD population including non-diabetic and lower-eGFR patients.

• Cautions: volume depletion, genital mycotic infections, euglycaemic diabetic ketoacidosis (in diabetics); rare Fournier's gangrene. Continue RAAS blockade in parallel.

Q6: Special populations — pregnancy, the elderly, Black/African ancestry (3 min)

"How does your approach to hypertensive CKD change in pregnancy, in the elderly, and in a patient of recent African ancestry?"

• Pregnancy: ACE inhibitors and ARBs are contraindicated at all stages (fetopathy). Stop before conception and switch to labetalol (first-line), methyldopa (second/third trimester) or nifedipine modified-release. Chronic hypertension in pregnancy increases pre-eclampsia, fetal growth restriction and abruption; if pre-eclampsia with severe features develops, give magnesium sulphate for seizure prophylaxis and deliver as definitive treatment.

• The elderly: usually have isolated systolic hypertension with a wide pulse pressure (stiff vasculature) and a high risk of orthostatic hypotension — always measure standing BP before intensifying therapy. SPRINT showed benefit of intensive control even over age 75, but exclude frailty and weigh falls risk. Prefer well-tolerated longer-acting agents (amlodipine, an ACEi/ARB, a thiazide-like diuretic).

• Black / African ancestry: higher hypertension prevalence, earlier onset, greater salt sensitivity, and APOL1 G1/G2 risk variants that drive a markedly higher risk of FSGS-like and hypertensive nephrosclerosis lesions with rapid progression to ESKD. ALLHAT showed thiazide-type diuretics (chlorthalidone) and CCBs are particularly effective initial agents in Black patients, but AASK established that an ACE inhibitor (ramipril) slows GFR decline better than amlodipine or metoprolol in those with established CKD or proteinuria — so an ACEi/ARB remains first-line in CKD, often with a CCB added. Emphasise early aggressive control and dietary sodium reduction; the first APOL1-targeted therapies (e.g., inaxaplin) are in trials.

References4ShowHide

1. [1]Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA, 2019.PMID 31573641
2. [2]Romagnani P, Remuzzi G, Glassock R, et al. Chronic kidney disease. Nature Reviews Disease Primers, 2017.PMID 29168475
3. [6]Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA, 2002.PMID 12435255
4. [9]Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 2020.PMID 32970396